CHDR InnoS™: A novel approach to consultancy in the pharmaceutical and biotech industry
CHDR has three decades of experience in innovative clinical drug research. During our long history, we have advised both large and small companies regarding their drug development programmes. In 2018, CHDR established InnoS™ (Innovation Services), a full-service international consultancy group that draws on our vast network of pharmacological and clinical expertise.
InnoS™ provides consultancy services on both a case-by-case basis and within the context of strategic partnerships with biotech companies, supplying interim Chief Medical Officers and/or Chief Scientific Officers as needed. This approach can be used to help develop a complete research strategy and/or to provide advice on an existing program. InnoS works closely with venture capitalists and investors in order to support biomedical and scientific due diligence built on CHDR's expertise in both drug development and the underlying scientific principles. InnoS also provides advice to governments and regulatory organisations in order to keep pace with the rapidly changing field of drug development. Knowledge sharing in the form of scientific publications, white papers, and educational programmes is also part of Innos's core activities.
- InnoS provides advice to pharmaceutical companies, biotech companies, investors, researchers with a new business plan, governments, and regulatory organisations.
- InnoS also forms strategic partnerships with biotech companies, providing knowledge, an interim CMO and/or CSO, and other resources essential to helping the company succeed.
- InnoS provides comprehensive services through every step in the development process, including the beginning phases of drug design, clinical drug development, and the post-marketing phase.
- Our consultants have an established track record in the pharmaceutical industry, including drug development, adding to the success of our business and academic network.
- InnoS provides a wide range of support services, including areas such as finance, administration, knowledge base development, database management, research, and medical writing.
- Because InnoS is a fully independent unit of CHDR, clients benefit from our expertise and enjoy access to CHDR's Clinical Research Unit and Biomarker Development programme, all while retaining the freedom to work with other partners in further drug development.
- InnoS is also affiliated with the 123 Innovation Initiative, a partnership between CHDR and investors aimed at closing the gap between the laboratory and market applications.
InnoS at a glance
- Establish a sound research & development strategy in close collaboration with company management
- Develop a question-based drug development plan for optimal cost effectiveness
- Analysis of preclinical data
- Optimisation and/or revision of development plans and target profiles, including addressing development issues, identifying indications, and optimising dosage
- Supply additional technical and clinical services and expertise with high-level operational feasibility using a vast network of medical and scientific experts; these services include:
- Developing innovative methods
- Identifying and utilising biomarkers
- Developing and applying PK/PD models and simulations
- Providing advice in emergent problems
- Providing strategic advice with respect to regulators
123 Innovation initiative
The 123 Innovation Initiative was created in collaboration with CHDR to provide nondilutive financing for early-stage clinical trials that are more effective, more informative and more efficient.The 123 Innovation Initiative is best suited for the following entities:
- Start-up companies seeking to obtain early clinical data without diluting their equity
- Academic programmes that need clinical data for creating spin-off businesses or partnerships with pharma companies
- Biotech companies that need to address specific questions without diluting their equity
- Programmes that have a promising approach but need to refocus after encountering initial roadblocks